He MK, et al. - Researchers investigated how the combination of sorafenib with hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone, the current standard systemic treatment, influences survival in patients with hepatocellular carcinoma and portal vein invasion. In this randomized clinical trial of 247 patients, a significantly longer median overall survival time (13.37 vs 7.13 months) and acceptable safety profiles were evident among patients receiving sorafenib plus hepatic arterial infusion chemotherapy vs those receiving sorafenib. The sorafenib plus hepatic arterial infusion chemotherapy group also had a greater response rate and longer median progression-free survival.